Equity Overview
Price & Market Data
Price: $14.80
Daily Change: -$0.90 / 6.08%
Daily Range: $14.04 - $15.65
Market Cap: $619,146,176
Daily Volume: 175,030
Performance Metrics
1 Week: -5.79%
1 Month: 41.09%
3 Months: 69.72%
6 Months: 86.87%
1 Year: -16.08%
YTD: 80.71%
Company Details
Employees: 130
Sector: Health technology
Industry: Biotechnology
Country:
Details
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.